Sign in or create an account to add this stock to your watchlist.
About Cellular Biomedicine Group (NASDAQ:CBMG)
Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer, orthopedic, and metabolic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint and autoimmune diseases; tumor cell specific dendritic cell therapy; and Re-Join therapy and AlloJoin therapy for the treatment of knee osteoarthritis. It also engages in the research and production of lab kits. The company has a strategic research collaboration with GE Healthcare Life Science to co-develop industrial control processes in chimeric antigen receptor T-cell and stem cell manufacturing. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in Cupertino, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CBMG
CUSIPN/A
Phone408-973-7884
Debt
Debt-to-Equity RatioN/A
Current Ratio9.36
Quick Ratio9.36
Price-To-Earnings
Trailing P/E Ratio-9.92
Forward P/E Ratio-10.90
P/E GrowthN/A
Sales & Book Value
Annual Sales$340,000.00
Price / Sales907.94
Cash FlowN/A
Price / CashN/A
Book Value$4.65 per share
Price / Book3.80
Profitability
EPS (Most Recent Fiscal Year)($1.78)
Net Income$-25,490,000.00
Net Margins-9,594.83%
Return on Equity-45.67%
Return on Assets-42.58%
Miscellaneous
Employees125
Outstanding Shares17,490,000
Cellular Biomedicine Group (NASDAQ:CBMG) Frequently Asked Questions
What is Cellular Biomedicine Group's stock symbol?
Cellular Biomedicine Group trades on the NASDAQ under the ticker symbol "CBMG."
How will Cellular Biomedicine Group's stock buyback program work?
Cellular Biomedicine Group declared that its board has authorized a share repurchase plan on Sunday, June 4th 2017, which allows the company to repurchase $10,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to purchase shares of its stock through open market purchases. Shares repurchase plans are typically an indication that the company's board believes its stock is undervalued.
How were Cellular Biomedicine Group's earnings last quarter?
Cellular Biomedicine Group Inc (NASDAQ:CBMG) posted its quarterly earnings data on Monday, May, 7th. The biotechnology company reported ($0.51) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.46) by $0.05. The biotechnology company had revenue of $0.05 million for the quarter, compared to analysts' expectations of $0.10 million. Cellular Biomedicine Group had a negative return on equity of 45.67% and a negative net margin of 9,594.83%. View Cellular Biomedicine Group's Earnings History.
When is Cellular Biomedicine Group's next earnings date?
What price target have analysts set for CBMG?
2 brokers have issued 1 year price objectives for Cellular Biomedicine Group's stock. Their predictions range from $18.00 to $32.00. On average, they expect Cellular Biomedicine Group's stock price to reach $25.00 in the next twelve months. View Analyst Ratings for Cellular Biomedicine Group.
What are Wall Street analysts saying about Cellular Biomedicine Group stock?
Here are some recent quotes from research analysts about Cellular Biomedicine Group stock:
- 1. According to Zacks Investment Research, "Cellular Biomedicine Group Inc. is a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases utilizing proprietary cell therapy technologies. The Company offers developmental stem cell, progenitor cell, and immune cell projects. It is developing treatments utilizing proprietary cell technologies for the treatment of a range of cancers; joint disease and central nervous system diseases. Cellular Biomedicine Group Inc. is headquartered in Palo Alto, California. " (5/23/2018)
- 2. Maxim Group analysts commented, "As Gilead pays $12 Billion for the planned acquisiton of Kite (KITE – $178.28 – Hold) and the market shifts focus to the remaining stand-alone CAR-T players such as JUNO (JUNO – $43.67 – Buy) and bluebird (BLUE – $103.88 – Buy) we see an opportunity with CBMG in China." (8/29/2017)
Who are some of Cellular Biomedicine Group's key competitors?
Some companies that are related to Cellular Biomedicine Group include Cellectis (CLLS), Adaptimmune Therapeutics (ADAP), Acorda Therapeutics (ACOR), Bavarian Nordic (BVNRY), Coherus BioSciences (CHRS), La Jolla Pharmaceutical (LJPC), Heska (HSKA), Solid Biosciences (SLDB), Novavax (NVAX), Voyager Therapeutics (VYGR), CASI Pharmaceuticals (CASI), Fate Therapeutics (FATE), BioCryst Pharmaceuticals (BCRX), Vericel (VCEL) and Mesoblast (MESO).
Who are Cellular Biomedicine Group's key executives?
Cellular Biomedicine Group's management team includes the folowing people:
- Mr. Bizuo Liu, Chief Exec. Officer, Interim Chief Financial Officer and Director (Age 53)
- Dr. Yihong Yao Ph.D., BS, Chief Scientific Officer (Age 50)
- Mr. Andrew K. Chan J.D., MBA, Sr. VP of Legal & Corp. Devel. and Board Sec. (Age 60)
- Dr. Xia Meng Ph.D., BS, Gen. Mang. of Early Diagnosis & Intervention
- Dr. Wen Tao Liu Ph.D., Strategic Advisor and Director (Age 62)
Has Cellular Biomedicine Group been receiving favorable news coverage?
News articles about CBMG stock have been trending somewhat positive recently, according to Accern. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cellular Biomedicine Group earned a coverage optimism score of 0.22 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 47.88 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
Who are Cellular Biomedicine Group's major shareholders?
Cellular Biomedicine Group's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Northern Trust Corp (0.22%) and Tibra Equities Europe Ltd (0.16%). Company insiders that own Cellular Biomedicine Group stock include Andrew K Chan, Tony Liu, Wen Tao Liu and Yihong Yao. View Institutional Ownership Trends for Cellular Biomedicine Group.
Which major investors are buying Cellular Biomedicine Group stock?
CBMG stock was acquired by a variety of institutional investors in the last quarter, including Tibra Equities Europe Ltd and Northern Trust Corp. Company insiders that have bought Cellular Biomedicine Group stock in the last two years include Andrew K Chan, Tony Liu and Yihong Yao. View Insider Buying and Selling for Cellular Biomedicine Group.
How do I buy shares of Cellular Biomedicine Group?
Shares of CBMG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cellular Biomedicine Group's stock price today?
One share of CBMG stock can currently be purchased for approximately $17.65.
How big of a company is Cellular Biomedicine Group?
Cellular Biomedicine Group has a market capitalization of $311.29 million and generates $340,000.00 in revenue each year. The biotechnology company earns $-25,490,000.00 in net income (profit) each year or ($1.78) on an earnings per share basis. Cellular Biomedicine Group employs 125 workers across the globe.
How can I contact Cellular Biomedicine Group?
Cellular Biomedicine Group's mailing address is 19925 STEVENS CREEK BLVD. SUITE 100, CUPERTINO CA, 95014. The biotechnology company can be reached via phone at 408-973-7884 or via email at [email protected]
MarketBeat Community Rating for Cellular Biomedicine Group (CBMG)
MarketBeat's community ratings are surveys of what our community members think about Cellular Biomedicine Group and other stocks. Vote "Outperform" if you believe CBMG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBMG will underperform the S&P 500 over the long term. You may vote once every thirty days.
Cellular Biomedicine Group (NASDAQ:CBMG) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for Cellular Biomedicine Group in the last 12 months. Their average twelve-month price target is $25.00, suggesting that the stock has a possible upside of 41.64%. The high price target for CBMG is $32.00 and the low price target for CBMG is $18.00. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Hold | Buy |
| Consensus Rating Score: | 2.50 | 2.50 | 2.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $25.00 | $25.00 | $18.00 | $18.00 |
| Price Target Upside: | 41.64% upside | 29.20% upside | 13.25% downside | 100.00% upside |
Cellular Biomedicine Group (NASDAQ:CBMG) Consensus Price Target History
Cellular Biomedicine Group (NASDAQ:CBMG) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 5/21/2018 | B. Riley | Set Price Target | Buy | $32.00 | Medium |  |
| 3/6/2018 | Maxim Group | Reiterated Rating | Hold | | Medium | |
(Data available from 5/23/2016 forward)
Cellular Biomedicine Group (NASDAQ:CBMG) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Cellular Biomedicine Group (NASDAQ CBMG) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 8.30%
Institutional Ownership Percentage: 4.09%
Cellular Biomedicine Group (NASDAQ CBMG) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/10/2018 | Wen Tao Liu | Director | Sell | 10,400 | $20.10 | $209,040.00 | 223,476 | |
| 12/22/2017 | Andrew K. Chan | SVP | Buy | 8,333 | $12.00 | $99,996.00 | | |
| 12/22/2017 | Tony Liu | CEO | Buy | 29,167 | $12.00 | $350,004.00 | | |
| 12/22/2017 | Yihong Yao | Insider | Buy | 4,167 | $12.00 | $50,004.00 | | |
| 6/6/2017 | Tony Liu | CEO | Buy | 10,000 | $6.83 | $68,300.00 | 119,825 | |
| 2/22/2016 | Andrew K Chan | SVP | Sell | 1,307 | $18.22 | $23,813.54 | 147,054 | |
| 2/17/2016 | Andrew K. Chan | SVP | Sell | 1,516 | $17.76 | $26,924.16 | 145,747 | |
| 1/21/2016 | Andrew K. Chan | SVP | Sell | 2,812 | $12.90 | $36,274.80 | 145,747 | |
| 12/21/2015 | Andrew K. Chan | SVP | Sell | 12,812 | $21.94 | $281,095.28 | 142,945 | |
| 11/23/2015 | Andrew K. Chan | SVP | Sell | 5,332 | $20.64 | $110,052.48 | 155,757 | |
| 10/21/2015 | Wei (William) Cao | CEO | Sell | 20,000 | $19.59 | $391,800.00 | 222,518 | |
| 10/20/2015 | Andrew K. Chan | SVP | Sell | 5,215 | $20.20 | $105,343.00 | 159,793 | |
| 9/21/2015 | Andrew K. Chan | SVP | Sell | 27,927 | $20.80 | $580,881.60 | 162,196 | |
| 12/23/2014 | Pak To Leung | Major Shareholder | Sell | 142,857 | $14.00 | $1,999,998.00 | | |
| 6/26/2014 | David Bolocan | Director | Buy | 10,000 | $5.00 | $50,000.00 | | |
| 5/22/2014 | Tony Liu | CFO | Buy | 100,000 | $5.00 | $500,000.00 | | |
| 7/23/2013 | Keith Wong | Director | Sell | 320,050 | $0.13 | $41,606.50 | | |
(Data available from 1/1/2013 forward)
Cellular Biomedicine Group (NASDAQ CBMG) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Q2 2018 Earnings Forecast for Cellular Biomedicine Group Inc Issued By B. Riley (CBMG)
www.americanbankingnews.com - May 23 at 6:44 AM |
| Cellular Biomedicine Group Inc to Post Q1 2019 Earnings of ($0.59) Per Share, B. Riley Forecasts (CBMG)
www.americanbankingnews.com - May 22 at 7:48 AM |
| Cellular Biomedicine Group (CBMG) Given a $32.00 Price Target at B. Riley
www.americanbankingnews.com - May 21 at 11:05 AM |
| Cellular Biomedicine Gr (CBMG) Downgraded by BidaskClub
www.americanbankingnews.com - May 10 at 1:02 PM |
| Cellular Biomedicine Gr (CBMG) Announces Earnings Results, Misses Estimates By $0.05 EPS
www.americanbankingnews.com - May 9 at 1:43 PM |
 | Cellular Biomedicine: 1Q Earnings Snapshot
finance.yahoo.com - May 8 at 9:34 AM |
| Cellular Biomedicine Group Reports First Quarter 2018 Financial Results and Highlights Operational Progress
finance.yahoo.com - May 8 at 9:34 AM |
| Should You Be Content With Cellular Biomedicine Group Inc’s (NASDAQ:CBMG) Earnings Growth?
finance.yahoo.com - May 7 at 4:27 PM |
| Cellular Biomedicine Group Announces Results of 2018 Annual Meeting of Stockholders
finance.yahoo.com - April 30 at 9:50 AM |
| Cellular Biomedicine Gr (CBMG) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - April 30 at 8:35 AM |
| Cellular Biomedicine (CBMG) Given $32.00 Consensus Target Price by Analysts
www.americanbankingnews.com - April 12 at 11:19 PM |
| Cellular Biomedicine (CBMG) Director Sells $209,040.00 in Stock
www.americanbankingnews.com - April 12 at 4:33 PM |
| ValuEngine Upgrades Cellular Biomedicine (CBMG) to Hold
www.americanbankingnews.com - April 5 at 2:03 PM |
| Cellular Biomedicine (CBMG) Upgraded to "Buy" at BidaskClub
www.americanbankingnews.com - March 29 at 4:44 PM |
| Maxim Group Downgrades Cellular Biomedicine (CBMG) to Hold
www.americanbankingnews.com - March 25 at 10:22 PM |
| Cellular Biomedicine Group (CBMG) Announces Annual Meeting of Stockholders
finance.yahoo.com - March 23 at 9:36 AM |
| Cellular Biomedicine Group Inc (CBMG) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 22 at 3:24 PM |
| Contrasting VIVUS (VVUS) & Cellular Biomedicine Group (CBMG)
www.americanbankingnews.com - March 20 at 11:46 AM |
| Wired News – Cellular Biomedicine's 48-Week Data off China-based Phase-I Clinical Trial Shows Positive Result for AlloJoin(TM) for Treatment of KOA
finance.yahoo.com - March 20 at 9:53 AM |
| Cellular Biomedicine Group's (CBMG) Buy Rating Reaffirmed at B. Riley
www.americanbankingnews.com - March 16 at 4:26 PM |
| B. Riley Weighs in on Cellular Biomedicine Group Inc's Q1 2018 Earnings (CBMG)
www.americanbankingnews.com - March 12 at 2:48 AM |
| Cellular Biomedicine Group (CBMG) Earns Buy Rating from Analysts at B. Riley
www.americanbankingnews.com - March 10 at 8:48 PM |
| Zacks: Cellular Biomedicine Group Inc (CBMG) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - March 8 at 5:24 AM |
| Cellular Biomedicine Group (CBMG) Releases Earnings Results, Misses Expectations By $0.08 EPS
www.americanbankingnews.com - March 7 at 10:24 AM |
 | BRIEF-Cellular Biomedicine Group Reports Full-Year 2017 Financial Results And Recent Operational Progress
www.reuters.com - March 7 at 9:46 AM |
| Cellular Biomedicine Group (CBMG) Given Hold Rating at Maxim Group
www.americanbankingnews.com - March 6 at 3:32 PM |
| Cellular Biomedicine Group Reports Full-Year 2017 Financial Results and Recent Operational Progress
finance.yahoo.com - March 6 at 9:31 AM |
| Cellular Biomedicine Group (CBMG) Set to Announce Earnings on Monday
www.americanbankingnews.com - March 5 at 2:16 AM |
| Contrasting Cellular Biomedicine Group (CBMG) & Spring Bank Pharmaceuticals (SBPH)
www.americanbankingnews.com - March 3 at 11:48 AM |
| Zacks: Cellular Biomedicine Group Inc (CBMG) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - March 2 at 7:24 PM |
| Cellular Biomedicine Group Invited to Present a Keynote Speech at Phar-East Asia Pharma & Biotech Festival
finance.yahoo.com - March 1 at 9:21 AM |
| Cellular Biomedicine Group Inc (CBMG) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - February 11 at 1:18 PM |
| Cellular Biomedicine Group Inc (CBMG) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - February 8 at 7:36 PM |
| BRIEF-Cellular Biomedicine Group Announces $30.6 Mln Investment From Sailing Capital Overseas Investment
www.reuters.com - February 6 at 4:33 PM |
| Cellular Biomedicine Group Announces $30.6 million Investment from Sailing Capital Overseas Investment Ltd.
finance.yahoo.com - February 5 at 9:00 AM |
| BRIEF-Cellular Biomedicine Announces Plan To Configure Part Of Shanghai Facility
www.reuters.com - January 18 at 5:07 PM |
| CBMG Accelerates Cell Therapy Manufacturing with GE Healthcare’s New Start-to-Finish Solution
finance.yahoo.com - January 18 at 5:07 PM |
| Cellular Biomedicine Group Inc (CBMG) Insider Yihong Yao Acquires 4,167 Shares
www.americanbankingnews.com - December 28 at 5:16 PM |
| Cellular Biomedicine Group Inc (CBMG) SVP Andrew K. Chan Buys 8,333 Shares
www.americanbankingnews.com - December 28 at 5:10 PM |
| Insider Buying: Cellular Biomedicine Group Inc (CBMG) CEO Acquires 29,167 Shares of Stock
www.americanbankingnews.com - December 28 at 3:42 PM |
| ETFs with exposure to Cellular Biomedicine Group, Inc. : December 28, 2017
finance.yahoo.com - December 28 at 12:37 PM |
| Cellular Biomedicine Group Announces Closing of $14.5 Million Private Placement Offering
finance.yahoo.com - December 28 at 12:37 PM |
| Cellular Biomedicine Group, Inc. :CBMG-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017
finance.yahoo.com - December 27 at 5:04 PM |
| BRIEF-Cellular Biomedicine Group reports qtrly loss per share $0.43
www.reuters.com - November 11 at 11:52 AM |
| Cellular Biomedicine Group Opens its New Shanghai GMP Facility and Joint Laboratory
finance.yahoo.com - November 7 at 7:56 PM |
| BRIEF-Thermo Fisher Scientific and Cellular Biomedicine announce partnership to develop manufacturing processes
www.reuters.com - November 6 at 6:11 PM |
 | Cellular Bio teams up with Fisher Scientific to build automated cell therapy manufacturing system
seekingalpha.com - November 6 at 6:11 PM |
| Thermo Fisher Scientific and Cellular Biomedicine Group Announce Strategic Partnership to Develop Manufacturing Processes
finance.yahoo.com - November 6 at 6:11 PM |
| Contrasting Cellular Biomedicine Group (CBMG) and Its Peers
www.americanbankingnews.com - November 6 at 3:15 PM |
| Cellular Biomedicine Group Executives to Present at Biotech and Money World HealthEx Forum in London
finance.yahoo.com - October 31 at 6:09 PM |
Cellular Biomedicine Group (NASDAQ:CBMG) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Cellular Biomedicine Group (NASDAQ:CBMG) Income Statement, Balance Sheet and Cash Flow Statement
Cellular Biomedicine Group (NASDAQ CBMG) Stock Chart for Wednesday, May, 23, 2018
Loading chart…
